Biomea Fusion Inc. (BMEA)
NASDAQ: BMEAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BMEA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $41.75M
- EPS (TTM)
- -$0.10
- Dividend yield
- None
- 52-week range
- 0.45 – 2.24
- Day range
- 0.5445 – 0.60
- Volume / Avg
- 1.12M / 2.22M
- Beta
- —
- Shares outstanding
- 72.68M
52-week range
BMEA stock today
Biomea Fusion (BMEA) closed at $0.5744 on Nov 20, down 2.38% (-$0.014), versus the S&P 500's 3.70% decline. Shares are 74.3% below their 52-week high of $2.24, set on Apr 20, 2026 and 27.6% above the 52-week low of $0.45, near the bottom of the past year's range. BMEA is down 53.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 41.5%.
Biomea Fusion has posted a net loss over the last twelve months (EPS of -$0.10), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Biomea Fusion
Company profileBiomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Michael J. M. Hitchcock Ph.D.
- Headquarters
- San Carlos, CA
- Employees
- 37
- IPO year
- 2021
- Website
- biomeafusion.com
Financial highlights
Full financialsBiomea Fusion reported a net loss of $61.8 million, compared with a loss of $138.4 million a year earlier. Diluted earnings per share came in at -$1.18.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-61.80M | $-138.43M | $-117.25M | $-81.83M | $-41.57M |
| EPS (diluted) | $-1.18 | $-3.83 | $-3.44 | $-2.80 | $-1.74 |
Analyst forecast
ForecastConsensus (8 analysts)
buy
Avg. price target
$7.00+1118.66%
- Strong buy 2
- Buy 5
- Hold 0
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.27 vs $-0.18
- Surprise
- -50.00%
BMEA news
All BMEA news- Biomea Fusion to Participate in Upcoming Investor ConferencesGlobeNewswire
- Biomea Fusion Reports Third Quarter 2026 Financial Results and Corporate HighlightsGlobeNewswire
- Weekly Buzz: RHHBY, TEVA Win FDA Nod; MLAB, GSK Cut Jobs; AZN, VIR Deals; KRYS, ABBV Report DataNasdaqABBV, ANL, ARWR, AZN
- Biomea Reports Phase 1 Weight-Loss Data For Oral GLP-1 Candidate BMF-650; Shares FallNasdaqBMEA, ET
- Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor AgonistGlobeNewswire
- Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor AgonistGlobeNewswire
Biomea Fusion peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MREOMereo BioPharma Group plc ADR | 0.26 | -5.45% | $41.52M | vs BMEA |
| OSTXOS Therapies Incorporated | 0.803 | -2.12% | $42.00M | vs BMEA |
| INCRIntercure Ltd. | 3.24 | -7.69% | $42.03M | vs BMEA |
| ELTXElicio Therapeutics Inc. | 1.45 | -3.33% | $41.05M | vs BMEA |
| CRBPCorbus Pharmaceuticals Holdings Inc. | 2.06 | -15.40% | $42.45M | vs BMEA |
| TLPHTalphera Inc. | 0.7852 | +6.25% | $40.80M | vs BMEA |
| SPROSpero Therapeutics Inc. | 0.742 | -10.20% | $43.23M | vs BMEA |
| RLYBRallybio Corporation | 15.47 | -0.32% | $43.32M | vs BMEA |
Indexes, lists and sector
Biomea Fusion stock FAQ
What is Biomea Fusion's stock price today?
BMEA last traded at $0.5744 as of Nov 20, 4:00 PM EST, down 2.38% on the day. Prices are delayed at least 15 minutes.
Who is Biomea Fusion's CEO?
Dr. Michael J. M. Hitchcock Ph.D. is the chief executive officer of Biomea Fusion Inc., which has about 37 employees.
What is the BMEA 52-week high?
The 52-week high for BMEA is $2.24 and the 52-week low is $0.45. The stock is currently 74.3% below its high.